Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Pioneer Pharma Completes $2.5 Million Investment in NovaBay

publication date: Nov 5, 2012
Pioneer Pharma, a Singapore company that is affiliated with Naqu Area Pioneer Pharma of Shanghai, completed a $2.5 million investment into California-based NovaBay® Pharma. The investment was part of deal that gives Pioneer the right to market NovaBay’s anti-infective wound-cleaning product, NeutroPhase, in China and Southeast Asia. The investment purchased two million units at a price of $1.25 each. Each unit consists of one share of NovaBay and a warrant to buy an additional share at a price of $1.50. NovaBay is currently trading at $1.31. More details....

Stock Symbol: (NYSE: NBY)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital